Intec Parent News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Intec parent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Intec Parent Today - Breaking & Trending Today
Q BioMed (OTCMKTS:QBIO – Get Rating) and Indaptus Therapeutics (NASDAQ:INDP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Profitability This table compares Q BioMed and Indaptus Therapeutics’ […] ....
Intec Closes Merger with Decoy Biosystems USA - English Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus News provided by Share this article Share this article NEW YORK, Aug. 3, 2021 /PRNewswire/ Indaptus Therapeutics, Inc. (Nasdaq: INDP) ( Indaptus or the Company, and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ( Decoy ) and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company s therapeutic focus. Indaptus is expected to begin trading on the Nasdaq Capital Market at the open of trading on August 4, 2021, under the ticker symbol INDP and a new CUSIP number (45339J 105). The previous ticker symbol was NTEC (Nasdaq: NTEC). The Company will have a new website address: www.indaptusrx.com. ....
Intec Announces Expected Closing Date of Decoy Merger prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Health your username 6 days ago A stockholder is suing Intec Pharma Ltd., Intec’s board of directors, and related entities over alleged violations of the Securities Exchange Act, per a Friday complaint filed in the District of Delaware regarding a proposed merger. Plaintiff Craig Davidson is an owner of common stock of Intec, a biopharmaceutical company developing drug products based on its Accordion Pill platform that seeks to “improve the efficacy and safety” of drug products. On March 15, Intec’s board of directors executed a merger agreement with Intec Parent, Inc., Dillion Merger Subsidiary Inc., Domestication Merger Sub Ltd., and Decoy Biosystems Inc. The companies said in a news release that they are aiming for the merger to be executed in the third quarter of 2021, the complaint detailed. A registration statement with the Securities and Exchange Commission (SEC) followed on April 20. ....